Figure 6: Decreased thymic selection of V α 14 NKT cells in CD1-TD mice. In summary, the CD1-TD knock-in mouse showed selective defects in CD1d-mediated antigen presentation. It allowed the ...

Yuan Liu from Georgia State University reports that intratumoral SIRPα-deficient macrophages activate tumor ... excellent antigen presenting cells that conduct immunogenic antigen presentation ...

Tumor antigens are captured and displayed by antigen processing and presentation machinery (APM) on the cell surface by HLA-I, making it possible for CD8 + T cells to eliminate cancer cells.

(3) Genetic modification of the T cells is performed by inserting the CAR gene, enabling them to recognize tumor-specific antigens. (4) CAR-T cells are expanded ex vivo to achieve sufficient ...

YTHDF1 controls the level of proteases that destroy potential tumor antigens. This limits their presentation to T cells. These limits were a problem, He said. But when he and his colleagues ...

Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma Colorectal cancer (CRC) remains a major global health ... CRC often ...

Scientists from the Moffitt Cancer Center say they now have a better understanding why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their ...

CAR+ cells denote CARv3-TEAM-E T cells, which are chimeric antigen receptor (CAR) T cells engineered to target the epidermal growth factor receptor (EGFR) variant III (EGFRvIII) tumor-specific ...

including those involved in antigen presentation and immune surveillance. Notably, this mechanistic interaction was found to be cell- and cancer-type agnostic, providing a generalized mechanism of ...

Details of the presentation are ... CB21 is a highly-potent T-cell engager molecule that targets LY6G6D, an emerging, next-generation tumor-specific antigen for treating colorectal cancer (CRC ...